NKT3964

NKT3964 is a first-in-class, highly potent and selective, orally bioavailable small molecule that functions as a proteolysis-targeting chimera (PROTAC) degrader of cyclin-dependent kinase 2 (CDK2). By selectively degrading CDK2, NKT3964 achieves prolonged inhibition of the CDK2 pathway without causing cyclin E accumulation. This mechanism is designed to maximally suppress the CDK2 pathway and fully harness the therapeutic benefits of CDK2 inhibition. The drug is being developed for patients with advanced or metastatic solid tumors characterized by aberrant activation of the CDK2/cyclin E pathway, including ovarian, endometrial, gastric cancers, and hormone receptor-positive breast cancer. NKT3964 is currently in Phase 1 clinical trials as a monotherapy for these indications[1][2][3][5][6].